# US 2026/0083746 A1 · Reduced dosing regimens for glaucoma treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083746 A1
- Document ID: US20260083746A1
- Status: Published application
- Kind: A1
- Application number: 19/339,566
- Filed: 2025-09-25
- Published: 2026-03-26
- Earliest claimed: 2024-09-25
- Assignees: Harrow IP, LLC
- Applicants: Harrow IP, LLC
- Inventors: Dennis Elias Saadeh
- Web page: https://patentgrep.com/patent/US20260083746A1

## CPC

- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/382: having six-membered rings, e.g. thioxanthenes (thiothixene A61K31/496)
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 31/5575: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 27/06: Antiglaucoma agents or miotics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods for treating open-angle glaucoma include transitioning a patient from a twice-per-day or more treatment regimen to a once-per-day treatment regimen. The once-per-day treatment include administering a single dose of a pharmaceutical composition including timolol or a pharmaceutically acceptable salt thereof, brimonidine or a pharmaceutically acceptable salt thereof, dorzolamide or a pharmaceutically acceptable salt thereof, and bimatoprost or a pharmaceutically acceptable salt thereof, once per day.

## Claims

### Claim 1

A method of treating glaucoma in a subject in need thereof comprising:
administering a pharmaceutical composition comprising timolol or a pharmaceutically acceptable salt thereof, brimonidine or a pharmaceutically acceptable salt thereof, dorzolamide or a pharmaceutically acceptable salt thereof, and bimatoprost or a pharmaceutically acceptable salt thereof to the subject in a single dose once per day.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is previously administered a single dose of the pharmaceutical composition twice per day or more, and further comprising reducing the frequency of the previous administration to once per day.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject's mean intraocular pressure is statistically similar to the intraocular pressure of a patient treated with a pharmaceutical composition comprising latanoprost every other evening and a pharmaceutical composition comprising dorzolamide and timolol every morning.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject's mean intraocular pressure is statistically similar to the intraocular pressure of a patient treated with a pharmaceutical composition comprising latanoprost every evening and a pharmaceutical composition comprising dorzolamide and timolol two times per day.

### Claim 5 (depends on 2)

The method of claim 2, wherein reducing the frequency of administering the pharmaceutical composition to once per day raises the diurnal intraocular pressure by no more than 0.4 mm Hg.

### Claim 6 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is preservative-free.

### Claim 7 (depends on 1)

The method of claim 1, wherein the administration is topical administration via eye drops.

### Claim 8 (depends on 1)

The method of claim 1, wherein the concentration of timolol or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is about 0.5% w/v.

### Claim 9 (depends on 1)

The method of claim 1, wherein the concentration of brimonidine or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is about 0.15% w/v.

### Claim 10 (depends on 1)

The method of claim 1, wherein the concentration of dorzolamide or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is about 2% w/v.

### Claim 11 (depends on 1)

The method of claim 1, wherein the concentration of bimatoprost or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is about 0.01% w/v.

### Claim 12 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition further comprises sodium citrate, sodium chloride, polysorbate 80, poloxamer 407, and water for injection.

### Claim 13

A method of treating glaucoma in a subject in need thereof comprising:
stopping administration of a pharmaceutical composition comprising latanoprost or a pharmaceutically acceptable salt thereof every evening and a pharmaceutical composition comprising dorzolamide or a pharmaceutically acceptable salt thereof and timolol or a pharmaceutically acceptable salt thereof two times per day; and
administering a pharmaceutical composition comprising timolol or a pharmaceutically acceptable salt thereof, brimonidine or a pharmaceutically acceptable salt thereof, dorzolamide or a pharmaceutically acceptable salt thereof, and bimatoprost or a pharmaceutically acceptable salt thereof to the subject once per day.

### Claim 14 (depends on 13)

The method of claim 13, wherein the subject is being administered the pharmaceutical composition comprising latanoprost or a pharmaceutically acceptable salt thereof every evening and the pharmaceutical composition comprising dorzolamide or a pharmaceutically acceptable salt thereof and timolol or a pharmaceutically acceptable salt thereof two times per day prior for the treatment of open-angle glaucoma prior to stopping the administration.

### Claim 15 (depends on 13)

The method of claim 13, wherein the pharmaceutical composition comprising timolol or a pharmaceutically acceptable salt thereof, brimonidine or a pharmaceutically acceptable salt thereof, dorzolamide or a pharmaceutically acceptable salt thereof, and bimatoprost or a pharmaceutically acceptable salt thereof is preservative-free.

### Claim 16 (depends on 13)

The method of claim 13, wherein:
the concentration of timolol or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is about 0.5% w/V;
the concentration of brimonidine or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is about 0.15% w/v;
the concentration of dorzolamide or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is about 2% w/v; and
the concentration of bimatoprost or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is about 0.01% w/v.

### Claim 17

A method of reducing patient burden during treatment for glaucoma in a subject in need thereof comprising:
stopping administration of a pharmaceutical composition comprising latanoprost or a pharmaceutically acceptable salt thereof every other evening and a pharmaceutical composition comprising dorzolamide or a pharmaceutically acceptable salt thereof and timolol or a pharmaceutically acceptable salt thereof every morning; and
administering a pharmaceutical composition comprising timolol or a pharmaceutically acceptable salt thereof, brimonidine or a pharmaceutically acceptable salt thereof, dorzolamide or a pharmaceutically acceptable salt thereof, and bimatoprost or a pharmaceutically acceptable salt thereof to the subject once per day.

### Claim 18 (depends on 17)

The method of claim 17, wherein the subject is being administered the pharmaceutical composition comprising latanoprost or a pharmaceutically acceptable salt thereof every evening and the pharmaceutical composition comprising dorzolamide or a pharmaceutically acceptable salt thereof and timolol or a pharmaceutically acceptable salt thereof two times per day prior for the treatment of open-angle glaucoma prior to stopping the administration.

### Claim 19 (depends on 17)

The method of claim 17, wherein the pharmaceutical composition comprising timolol or a pharmaceutically acceptable salt thereof, brimonidine or a pharmaceutically acceptable salt thereof, dorzolamide or a pharmaceutically acceptable salt thereof, and bimatoprost or a pharmaceutically acceptable salt thereof is preservative-free.

### Claim 20 (depends on 17)

The method of claim 17, wherein:
the concentration of timolol or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is about 0.5% w/v;
the concentration of brimonidine or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is about 0.15% w/v;
the concentration of dorzolamide or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is about 2% w/v; and
the concentration of bimatoprost or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is about 0.01% w/v.
